Magdalena Kijowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magdalena Kijowska has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Karolina Klusek
Medical University of Lublin, Poland
14 shared publications - Aleksandra Magdalena Skrzyniarz
Medical University of Lublin, Lublin, Poland
10 shared publications - Aleksandra Zynkowska
Medical University of Lublin, Lublin, Poland
10 shared publications - Jakub Jakubowski
Medical University of Warsaw, Warsaw, Poland
10 shared publications - Julia OzięBło
Medical University of Lublin, Lublin, Poland
10 shared publications - Karol Kraska
Medical University of Lublin, Lublin, Poland
10 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
GLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes mellitus and obesity, are increasingly being investigated for their potential relevance to psychiatric disorders. Accumulating preclinical and clinical evidence indicates that GLP-1 signaling extends beyond metabolic regulation and may influence central mechanisms implicated in mood regulation, motivational processing, compulsive reward-seeking, and interoceptive control. This review synthesizes current mechanistic, preclinical, clinical, and registry-based evidence concerning the possible role of GLP-1 RAs in psychiatry, with particular emphasis on major depressive disorder, substance use disorders, and eating disorders. The biological rationale for their psychiatric relevance is supported by evidence of GLP-1-mediated signaling through circumventricular organs, vagal–brainstem pathways, and selected central nervous system regions, including hypothalamic, hippocampal, and mesolimbic reward-related circuits. Proposed mechanisms include modulation of reward salience, attenuation of neuroinflammatory signaling, improvement of metabolic-inflammatory burden, and enhancement of neuroplastic processes. The clinical evidence remains heterogeneous and indication-specific. In depression, the most consistent findings relate to cognitive and motivational domains, particularly in patients with major depressive disorder and coexisting overweight or obesity, whereas broader evidence from metabolic trials suggests modest reductions in depressive symptoms without establishing disorder-specific antidepressant efficacy. In substance use disorders, alcohol use disorder currently represents the most advanced area of investigation, with semaglutide demonstrating favorable outcomes in a phase 2 trial, while exenatide showed no overall reduction in heavy drinking but reduced alcohol cue reactivity and suggested potential benefit in obese participants. Evidence for nicotine use disorder is mixed, and data concerning opioid and stimulant use disorders remain preliminary. In eating disorders, binge-eating phenotypes appear to be the most plausible therapeutic target, whereas evidence for bulimia nervosa is limited and anorexia-spectrum disorders raise important safety concerns due to appetite suppression and weight loss. Overall, the safety profile of GLP-1 RAs in psychiatric populations appears broadly consistent with their established metabolic use, with gastrointestinal adverse effects predominating; however, psychiatric monitoring remains advisable because observational safety data are not fully concordant. Current evidence supports further diagnosis-specific randomized controlled trials but does not yet justify routine psychiatric prescribing outside carefully selected clinical contexts or research settings.
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessGLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes mellitus and obesity, are increasingly being investigated for their potential relevance to psychiatric disorders. Accumulating preclinical and clinical evidence indicates that GLP-1 signaling extends beyond metabolic regulation and may influence central mechanisms implicated in mood regulation, motivational processing, compulsive reward-seeking, and interoceptive control. This review synthesizes current mechanistic, preclinical, clinical, and registry-based evidence concerning the possible role of GLP-1 RAs in psychiatry, with particular emphasis on major depressive disorder, substance use disorders, and eating disorders. The biological rationale for their psychiatric relevance is supported by evidence of GLP-1-mediated signaling through circumventricular organs, vagal–brainstem pathways, and selected central nervous system regions, including hypothalamic, hippocampal, and mesolimbic reward-related circuits. Proposed mechanisms include modulation of reward salience, attenuation of neuroinflammatory signaling, improvement of metabolic-inflammatory burden, and enhancement of neuroplastic processes. The clinical evidence remains heterogeneous and indication-specific. In depression, the most consistent findings relate to cognitive and motivational domains, particularly in patients with major depressive disorder and coexisting overweight or obesity, whereas broader evidence from metabolic trials suggests modest reductions in depressive symptoms without establishing disorder-specific antidepressant efficacy. In substance use disorders, alcohol use disorder currently represents the most advanced area of investigation, with semaglutide demonstrating favorable outcomes in a phase 2 trial, while exenatide showed no overall reduction in heavy drinking but reduced alcohol cue reactivity and suggested potential benefit in obese participants. Evidence for nicotine use disorder is mixed, and data concerning opioid and stimulant use disorders remain preliminary. In eating disorders, binge-eating phenotypes appear to be the most plausible therapeutic target, whereas evidence for bulimia nervosa is limited and anorexia-spectrum disorders raise important safety concerns due to appetite suppression and weight loss. Overall, the safety profile of GLP-1 RAs in psychiatric populations appears broadly consistent with their established metabolic use, with gastrointestinal adverse effects predominating; however, psychiatric monitoring remains advisable because observational safety data are not fully concordant. Current evidence supports further diagnosis-specific randomized controlled trials but does not yet justify routine psychiatric prescribing outside carefully selected clinical contexts or research settings.
- Open Access
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
SLEEP DISORDERS AS A RISK FACTOR FOR HYPERTENSION
Sleep disorders are among the most prevalent health problems in modern society and are increasingly recognized as an important risk factor for cardiovascular diseases. Growing evidence indicates that insufficient sleep duration, poor sleep quality, and conditions such as insomnia or obstructive sleep apnea may contribute to the development of arterial hypertension. Sleep plays a crucial role in maintaining systemic homeostasis by regulating neurological, endocrine, and metabolic functions. Sleep disturbances may lead to chronic activation of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, promoting inflammatory processes and impairing blood pressure regulation. An increasing body of evidence suggests that impaired sleep negatively affects overall health and may contribute to the development of multiple chronic diseases. Sleep disturbances frequently coexist with other cardiovascular risk factors, including chronic stress, obesity, physical inactivity, and unhealthy dietary habits, thereby amplifying their adverse effects. Persistent deterioration in sleep quality may result in metabolic, hormonal, and cardiovascular dysfunction, increasing the risk of long-term health complications and reducing quality of life. In light of current evidence, adequate sleep duration and quality should be considered essential components of hypertension prevention and public health promotion strategies.
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessSLEEP DISORDERS AS A RISK FACTOR FOR HYPERTENSION
Sleep disorders are among the most prevalent health problems in modern society and are increasingly recognized as an important risk factor for cardiovascular diseases. Growing evidence indicates that insufficient sleep duration, poor sleep quality, and conditions such as insomnia or obstructive sleep apnea may contribute to the development of arterial hypertension. Sleep plays a crucial role in maintaining systemic homeostasis by regulating neurological, endocrine, and metabolic functions. Sleep disturbances may lead to chronic activation of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, promoting inflammatory processes and impairing blood pressure regulation. An increasing body of evidence suggests that impaired sleep negatively affects overall health and may contribute to the development of multiple chronic diseases. Sleep disturbances frequently coexist with other cardiovascular risk factors, including chronic stress, obesity, physical inactivity, and unhealthy dietary habits, thereby amplifying their adverse effects. Persistent deterioration in sleep quality may result in metabolic, hormonal, and cardiovascular dysfunction, increasing the risk of long-term health complications and reducing quality of life. In light of current evidence, adequate sleep duration and quality should be considered essential components of hypertension prevention and public health promotion strategies.
- Open Access
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
OPIOID-FREE AND OPIOID-SPARING ANESTHESIA IN MODERN PERIOPERATIVE CARE — BENEFITS, LIMITATIONS, AND CLINICAL APPLICATIONS
Opioid-free anesthesia (OFA) and opioid-sparing anesthesia (OSA) have emerged from two converging developments in perioperative medicine: first, the need to reduce opioid-related adverse drug events such as postoperative nausea and vomiting (PONV), respiratory depression, ileus, sedation, and possibly persistent postoperative use; and second, the maturation of enhanced recovery pathways built around multimodal, function-oriented analgesia. In contemporary evidence, however, strict elimination of intraoperative opioids has not shown universal superiority over well-conducted opioid-based anesthesia (OBA) for postoperative pain control or 24-hour opioid consumption. The most reproducible benefit of OFA is lower PONV in selected settings, whereas the most important safety signal is regimen-dependent bradycardia and hemodynamic instability, especially in dexmedetomidine-heavy protocols. By contrast, broader OSA strategies, particularly when built on acetaminophen, NSAIDs, regional anesthesia, judicious total intravenous anesthesia (TIVA), and selected adjuvants such as ketamine or lidocaine, are aligned with ERAS and other major perioperative guidance and have the strongest overall clinical support. This narrative review examines definitions, mechanisms, pharmacology, protocols, clinical outcomes, limitations, and practical applications of OFA and OSA in modern perioperative care. Conclusion: contemporary perioperative practice is better supported by individualized opioid stewardship and multimodal opioid-sparing care than by a dogmatic “zero-opioid” rule. OFA remains a reasonable option in selected phenotypes and procedures, but current evidence does not justify its routine use as a default replacement for all opioid-inclusive techniques.
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessOPIOID-FREE AND OPIOID-SPARING ANESTHESIA IN MODERN PERIOPERATIVE CARE — BENEFITS, LIMITATIONS, AND CLINICAL APPLICATIONS
Opioid-free anesthesia (OFA) and opioid-sparing anesthesia (OSA) have emerged from two converging developments in perioperative medicine: first, the need to reduce opioid-related adverse drug events such as postoperative nausea and vomiting (PONV), respiratory depression, ileus, sedation, and possibly persistent postoperative use; and second, the maturation of enhanced recovery pathways built around multimodal, function-oriented analgesia. In contemporary evidence, however, strict elimination of intraoperative opioids has not shown universal superiority over well-conducted opioid-based anesthesia (OBA) for postoperative pain control or 24-hour opioid consumption. The most reproducible benefit of OFA is lower PONV in selected settings, whereas the most important safety signal is regimen-dependent bradycardia and hemodynamic instability, especially in dexmedetomidine-heavy protocols. By contrast, broader OSA strategies, particularly when built on acetaminophen, NSAIDs, regional anesthesia, judicious total intravenous anesthesia (TIVA), and selected adjuvants such as ketamine or lidocaine, are aligned with ERAS and other major perioperative guidance and have the strongest overall clinical support. This narrative review examines definitions, mechanisms, pharmacology, protocols, clinical outcomes, limitations, and practical applications of OFA and OSA in modern perioperative care. Conclusion: contemporary perioperative practice is better supported by individualized opioid stewardship and multimodal opioid-sparing care than by a dogmatic “zero-opioid” rule. OFA remains a reasonable option in selected phenotypes and procedures, but current evidence does not justify its routine use as a default replacement for all opioid-inclusive techniques.
- Open Access
- 4 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
IS RADIATION THERAPY STILL USED IN THE TREATMENT OF GASTRIC CANCER?
Gastric cancer is one of the most prominent global health challenges. Despite recent declines in incidence and mortality, this cancer remains the fifth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. The treatment of gastric cancer requires a multidisciplinary approach, the choice of which depends on the stage of the disease and the patient’s overall condition. The mainstay of treatment is surgical resection with D2 lymphadenectomy and adjuvant or neoadjuvant radio- and chemotherapy. Currently, radiation therapy is widely used in several critical areas of gastric cancer treatment. Aim: The aim of this study is to evaluate the current use and effectiveness of radiotherapy in the treatment of gastric cancer, as well as the prospects for the further development of this therapeutic method. Material and methods: This study is based on a systematic review of several dozen scientific publications identified through PubMed and Google Schoolar databases using keywords “gastric cancer”, “radiotherapy”, “chemoradiotherapy”. Conclusions: In clinical practice, radiotherapy is primarily used as an adjuvant treatment. In perioperative therapy, it is combined with chemotherapy before surgery to reduce tumor size and after surgery to reduce the risk of recurrence and the development of micrometastases. Additionally, it is used as a palliative treatment for patients with advanced-stage disease who are not eligible for surgery. Emerging evidence also suggests potential benefits of incorporating radiotherapy into the management of patients with limited metastatic disease.
- 4 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessIS RADIATION THERAPY STILL USED IN THE TREATMENT OF GASTRIC CANCER?
Gastric cancer is one of the most prominent global health challenges. Despite recent declines in incidence and mortality, this cancer remains the fifth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. The treatment of gastric cancer requires a multidisciplinary approach, the choice of which depends on the stage of the disease and the patient’s overall condition. The mainstay of treatment is surgical resection with D2 lymphadenectomy and adjuvant or neoadjuvant radio- and chemotherapy. Currently, radiation therapy is widely used in several critical areas of gastric cancer treatment. Aim: The aim of this study is to evaluate the current use and effectiveness of radiotherapy in the treatment of gastric cancer, as well as the prospects for the further development of this therapeutic method. Material and methods: This study is based on a systematic review of several dozen scientific publications identified through PubMed and Google Schoolar databases using keywords “gastric cancer”, “radiotherapy”, “chemoradiotherapy”. Conclusions: In clinical practice, radiotherapy is primarily used as an adjuvant treatment. In perioperative therapy, it is combined with chemotherapy before surgery to reduce tumor size and after surgery to reduce the risk of recurrence and the development of micrometastases. Additionally, it is used as a palliative treatment for patients with advanced-stage disease who are not eligible for surgery. Emerging evidence also suggests potential benefits of incorporating radiotherapy into the management of patients with limited metastatic disease.
- Open Access
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
ROLE OF ANTIFIBRINOLYTIC THERAPY IN GYNECOLOGIC SURGERY: TRANEXAMIC ACID FOR REDUCING PERIOPERATIVE BLOOD LOSS
Perioperative hemorrhage remains an important clinical concern in gynecologic surgery, including hysterectomy, myomectomy, cesarean delivery, and oncologic procedures, as excessive blood loss may contribute to postoperative anemia, transfusion requirements, reoperation, prolonged hospitalization, and increased perioperative morbidity. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that reversibly binds to plasminogen and inhibits its conversion to plasmin, thereby reducing fibrin degradation and stabilizing formed clots. This review evaluates current evidence regarding the pharmacological properties, dosing strategies, efficacy, and safety profile of TXA in gynecologic surgical practice. Available randomized controlled trials and meta-analyses indicate that prophylactic administration of TXA, most commonly as a 1 g intravenous dose before surgical incision, significantly reduces intraoperative and postoperative blood loss across several gynecologic procedures. In benign hysterectomy, a large randomized controlled trial involving 332 patients demonstrated that intravenous TXA significantly decreased mean blood loss compared with placebo and reduced the incidence of bleeding exceeding 500 mL, as well as the need for reoperation due to postoperative hemorrhage. Evidence from myomectomy studies similarly suggests a clinically relevant reduction in perioperative blood loss, with meta-analytic data showing an average decrease of approximately 213 mL. In cesarean delivery, pooled data from randomized trials have shown that prophylactic TXA reduces total blood loss, transfusion rates, hemoglobin decline, and the need for additional uterotonic agents in both low- and high-risk patients. Comparable benefits have also been reported in selected gynecologic oncology procedures and after cervical conization. Importantly, across available studies, standard perioperative doses of TXA have not been associated with a significant increase in thromboembolic complications, although careful patient selection remains necessary, particularly in individuals with active thromboembolic disease or severe renal impairment. Overall, current evidence supports TXA as an effective, safe, and cost-efficient adjunct for reducing perioperative bleeding and transfusion requirements in gynecologic surgery. Future research should focus on defining optimal dosing and timing protocols for specific surgical subgroups, including extensive oncologic debulking procedures and complex endometriosis surgery, as well as evaluating long-term safety outcomes.
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessROLE OF ANTIFIBRINOLYTIC THERAPY IN GYNECOLOGIC SURGERY: TRANEXAMIC ACID FOR REDUCING PERIOPERATIVE BLOOD LOSS
Perioperative hemorrhage remains an important clinical concern in gynecologic surgery, including hysterectomy, myomectomy, cesarean delivery, and oncologic procedures, as excessive blood loss may contribute to postoperative anemia, transfusion requirements, reoperation, prolonged hospitalization, and increased perioperative morbidity. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that reversibly binds to plasminogen and inhibits its conversion to plasmin, thereby reducing fibrin degradation and stabilizing formed clots. This review evaluates current evidence regarding the pharmacological properties, dosing strategies, efficacy, and safety profile of TXA in gynecologic surgical practice. Available randomized controlled trials and meta-analyses indicate that prophylactic administration of TXA, most commonly as a 1 g intravenous dose before surgical incision, significantly reduces intraoperative and postoperative blood loss across several gynecologic procedures. In benign hysterectomy, a large randomized controlled trial involving 332 patients demonstrated that intravenous TXA significantly decreased mean blood loss compared with placebo and reduced the incidence of bleeding exceeding 500 mL, as well as the need for reoperation due to postoperative hemorrhage. Evidence from myomectomy studies similarly suggests a clinically relevant reduction in perioperative blood loss, with meta-analytic data showing an average decrease of approximately 213 mL. In cesarean delivery, pooled data from randomized trials have shown that prophylactic TXA reduces total blood loss, transfusion rates, hemoglobin decline, and the need for additional uterotonic agents in both low- and high-risk patients. Comparable benefits have also been reported in selected gynecologic oncology procedures and after cervical conization. Importantly, across available studies, standard perioperative doses of TXA have not been associated with a significant increase in thromboembolic complications, although careful patient selection remains necessary, particularly in individuals with active thromboembolic disease or severe renal impairment. Overall, current evidence supports TXA as an effective, safe, and cost-efficient adjunct for reducing perioperative bleeding and transfusion requirements in gynecologic surgery. Future research should focus on defining optimal dosing and timing protocols for specific surgical subgroups, including extensive oncologic debulking procedures and complex endometriosis surgery, as well as evaluating long-term safety outcomes.
- Open Access
- 21 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
ADVANCES IN THE DIAGNOSIS AND SURGICAL MANAGEMENT OF CHOLESTEATOMA: A CONTEMPORARY REVIEW
Cholesteatoma is a chronic, locally destructive disease of the middle ear characterized by the presence of keratinizing stratified squamous epithelium within the tympanic cavity and mastoid process. Despite its histologically benign nature, it may lead to the destruction of bony structures, damage to the auditory ossicles, and the development of serious intra- and extracranial complications. Its complex pathogenesis and tendency to recur make cholesteatoma a significant diagnostic and therapeutic challenge. In recent years, substantial progress has been made in both the diagnosis and surgical treatment of cholesteatoma. High-resolution computed tomography and magnetic resonance imaging with non-echo-planar diffusion-weighted imaging (non-EPI DWI) sequences enable accurate assessment of primary, residual, and recurrent lesions. Surgical treatment remains the cornerstone of therapy, while advances in endoscopic techniques have improved visualization of anatomical structures and enhanced surgical effectiveness while reducing invasiveness. Artificial intelligence systems are also gaining increasing importance in supporting imaging analysis, treatment planning, and clinical decision-making. The aim of this review is to present current advances in the diagnosis and surgical management of cholesteatoma, with particular emphasis on modern imaging techniques, endoscopic ear surgery, and applications of artificial intelligence. The development of these technologies may contribute in the future to improved treatment outcomes and reduced risk of disease recurrence.
- 21 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessADVANCES IN THE DIAGNOSIS AND SURGICAL MANAGEMENT OF CHOLESTEATOMA: A CONTEMPORARY REVIEW
Cholesteatoma is a chronic, locally destructive disease of the middle ear characterized by the presence of keratinizing stratified squamous epithelium within the tympanic cavity and mastoid process. Despite its histologically benign nature, it may lead to the destruction of bony structures, damage to the auditory ossicles, and the development of serious intra- and extracranial complications. Its complex pathogenesis and tendency to recur make cholesteatoma a significant diagnostic and therapeutic challenge. In recent years, substantial progress has been made in both the diagnosis and surgical treatment of cholesteatoma. High-resolution computed tomography and magnetic resonance imaging with non-echo-planar diffusion-weighted imaging (non-EPI DWI) sequences enable accurate assessment of primary, residual, and recurrent lesions. Surgical treatment remains the cornerstone of therapy, while advances in endoscopic techniques have improved visualization of anatomical structures and enhanced surgical effectiveness while reducing invasiveness. Artificial intelligence systems are also gaining increasing importance in supporting imaging analysis, treatment planning, and clinical decision-making. The aim of this review is to present current advances in the diagnosis and surgical management of cholesteatoma, with particular emphasis on modern imaging techniques, endoscopic ear surgery, and applications of artificial intelligence. The development of these technologies may contribute in the future to improved treatment outcomes and reduced risk of disease recurrence.
- Open Access
- 20 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
FUTURE PROSPECTS FOR ACNE TREATMENT- ARTIFICIAL INTELLIGENCE, NANOMEDICINE AND PRECISION DERMATOLOGY: A COMPREHENSIVE REVIEW
Acne vulgaris is one of the most common chronic inflammatory skin diseases with a complex and multifactorial pathogenesis, including keratinization disorders, excessive sebum production, skin microbiome dysbiosis, inflammatory processes, and hormonal and genetic factors. Despite the availability of numerous effective therapies, such as retinoids, antibiotics, and hormonal therapy, their use is still associated with limitations, including adverse effects, unsatisfactory results, the risk of antibiotic resistance, and disease recurrence. Consequently, contemporary dermatology is increasingly focusing on the development of personalized therapies and modern technologies supporting the diagnosis and treatment of acne. The aim of this study was to review current trends in the diagnosis and treatment of acne vulgaris, which are aimed at combining digital and biotechnological tools and exploring new treatment alternatives to improve treatment effectiveness. Data were analyzed regarding the use of artificial intelligence algorithms in assessing skin lesions, the use of nanocarriers in drug delivery, and the importance of genetic, immunological, hormonal, and microbiological factors in the pathogenesis of acne. The complex and multifactorial nature of acne vulgaris pathogenesis suggests that effective future therapies will require a multifaceted approach that takes into account individual patient predispositions.
- 20 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessFUTURE PROSPECTS FOR ACNE TREATMENT- ARTIFICIAL INTELLIGENCE, NANOMEDICINE AND PRECISION DERMATOLOGY: A COMPREHENSIVE REVIEW
Acne vulgaris is one of the most common chronic inflammatory skin diseases with a complex and multifactorial pathogenesis, including keratinization disorders, excessive sebum production, skin microbiome dysbiosis, inflammatory processes, and hormonal and genetic factors. Despite the availability of numerous effective therapies, such as retinoids, antibiotics, and hormonal therapy, their use is still associated with limitations, including adverse effects, unsatisfactory results, the risk of antibiotic resistance, and disease recurrence. Consequently, contemporary dermatology is increasingly focusing on the development of personalized therapies and modern technologies supporting the diagnosis and treatment of acne. The aim of this study was to review current trends in the diagnosis and treatment of acne vulgaris, which are aimed at combining digital and biotechnological tools and exploring new treatment alternatives to improve treatment effectiveness. Data were analyzed regarding the use of artificial intelligence algorithms in assessing skin lesions, the use of nanocarriers in drug delivery, and the importance of genetic, immunological, hormonal, and microbiological factors in the pathogenesis of acne. The complex and multifactorial nature of acne vulgaris pathogenesis suggests that effective future therapies will require a multifaceted approach that takes into account individual patient predispositions.
- Open Access
- 14 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
ROTATIONAL STABILITY AFTER ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION COMBINED WITH ANTEROLATERAL AUGMENTATION
Background and Objective: Residual rotational instability after anterior cruciate ligament reconstruction remains a clinically relevant problem, particularly in young and active patients returning to cutting and pivoting sports. This structured narrative review evaluates whether anterior cruciate ligament reconstruction combined with anterolateral augmentation improves rotational stability compared with isolated reconstruction. Methods: A structured PubMed search was conducted for English-language studies published between 2013 and 2025 addressing anterior cruciate ligament reconstruction, anterolateral ligament reconstruction, lateral extra-articular tenodesis, rotational instability, and pivot shift. Comparative clinical studies, randomized trials, systematic reviews, meta-analyses, and relevant biomechanical investigations were prioritized. Results: Current evidence suggests that combined reconstruction provides more consistent pivot-shift control than isolated anterior cruciate ligament reconstruction, especially in selected high-risk groups such as young athletes, patients with high-grade pivot shift, and selected revision cases. Randomized and pooled evidence also indicates reduced graft failure rates in some high-risk cohorts, although patient-reported functional outcomes are often similar between isolated and combined procedures. Conclusions: Combined anterior cruciate ligament reconstruction with anterolateral augmentation may enhance rotational stability and reduce failure risk in selected patients. However, routine use in all primary reconstructions cannot be recommended without stronger standardized long-term evidence.
- 14 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessROTATIONAL STABILITY AFTER ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION COMBINED WITH ANTEROLATERAL AUGMENTATION
Background and Objective: Residual rotational instability after anterior cruciate ligament reconstruction remains a clinically relevant problem, particularly in young and active patients returning to cutting and pivoting sports. This structured narrative review evaluates whether anterior cruciate ligament reconstruction combined with anterolateral augmentation improves rotational stability compared with isolated reconstruction. Methods: A structured PubMed search was conducted for English-language studies published between 2013 and 2025 addressing anterior cruciate ligament reconstruction, anterolateral ligament reconstruction, lateral extra-articular tenodesis, rotational instability, and pivot shift. Comparative clinical studies, randomized trials, systematic reviews, meta-analyses, and relevant biomechanical investigations were prioritized. Results: Current evidence suggests that combined reconstruction provides more consistent pivot-shift control than isolated anterior cruciate ligament reconstruction, especially in selected high-risk groups such as young athletes, patients with high-grade pivot shift, and selected revision cases. Randomized and pooled evidence also indicates reduced graft failure rates in some high-risk cohorts, although patient-reported functional outcomes are often similar between isolated and combined procedures. Conclusions: Combined anterior cruciate ligament reconstruction with anterolateral augmentation may enhance rotational stability and reduce failure risk in selected patients. However, routine use in all primary reconstructions cannot be recommended without stronger standardized long-term evidence.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
PREMENSTRUAL DYSPHORIC DISORDER (PMDD): CURRENT PHARMACOTHERAPY AND EMERGING TREATMENT APPROACHES
Premenstrual dysphoric disorder (PMDD) is a cyclic mood disorder affecting a subset of women in the late luteal phase, marked by severe affective and physical symptoms that resolve with menses. It is distinguished from milder premenstrual syndrome (PMS) by symptom severity and functional impairment. PMDD causes substantial distress: women with PMDD have functional impairments comparable to other depressive disorders and increased work absences, and PMDD is associated with higher rates of suicidal ideation and attempts. First-line pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs) and hormone-based treatments. SSRIs (e.g. sertraline, fluoxetine, paroxetine, escitalopram) are effective when dosed continuously or in the luteal phase, often producing rapid symptom relief at low doses. Hormonal therapies (e.g. combined oral contraceptives with drospirenone/ethinyl estradiol, GnRH agonists with add-back) can mitigate symptoms by suppressing cyclic ovarian hormone fluctuations. Emerging treatments target PMDD’s neuroendocrine underpinnings: for example, sepranolone (an allopregnanolone antagonist) has shown promising early results. Novel approaches under investigation include neurosteroid modulators, anti-inflammatory strategies, and personalized interventions (genetic or biomarker-driven therapy). This review summarizes current evidence-based pharmacotherapies for PMDD and discusses emerging treatment avenues based on advances in PMDD neurobiology and psychoneuroendocrinology.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessPREMENSTRUAL DYSPHORIC DISORDER (PMDD): CURRENT PHARMACOTHERAPY AND EMERGING TREATMENT APPROACHES
Premenstrual dysphoric disorder (PMDD) is a cyclic mood disorder affecting a subset of women in the late luteal phase, marked by severe affective and physical symptoms that resolve with menses. It is distinguished from milder premenstrual syndrome (PMS) by symptom severity and functional impairment. PMDD causes substantial distress: women with PMDD have functional impairments comparable to other depressive disorders and increased work absences, and PMDD is associated with higher rates of suicidal ideation and attempts. First-line pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs) and hormone-based treatments. SSRIs (e.g. sertraline, fluoxetine, paroxetine, escitalopram) are effective when dosed continuously or in the luteal phase, often producing rapid symptom relief at low doses. Hormonal therapies (e.g. combined oral contraceptives with drospirenone/ethinyl estradiol, GnRH agonists with add-back) can mitigate symptoms by suppressing cyclic ovarian hormone fluctuations. Emerging treatments target PMDD’s neuroendocrine underpinnings: for example, sepranolone (an allopregnanolone antagonist) has shown promising early results. Novel approaches under investigation include neurosteroid modulators, anti-inflammatory strategies, and personalized interventions (genetic or biomarker-driven therapy). This review summarizes current evidence-based pharmacotherapies for PMDD and discusses emerging treatment avenues based on advances in PMDD neurobiology and psychoneuroendocrinology.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
THE ROLE OF ELECTROCARDIOGRAPHY IN THE DIAGNOSIS AND MONITORING OF FABRY DISEASE: A COMPREHENSIVE REVIEW
Anderson-Fabry disease (FD) is a rare, X-linked lysosomal storage disorder in which the progressive accumulation of globotriaosylceramide (Gb3) leads to widespread multi-organ damage, with cardiac involvement serving as the primary cause of mortality. This comprehensive review aims to summarize the current state of knowledge regarding the clinical application of electrocardiography (ECG) as a pivotal and cost-effective tool in the management of patients with FD. The paper systematically categorizes ECG findings across the various stages of the disease's progression. Early stages are typically characterized by a shortened PR interval and increased QRS complex voltages, which frequently manifest prior to the development of structural changes identifiable through echocardiography. In the more advanced stages of the disease, the predominant features include signs of left ventricular hypertrophy (LVH), ST-segment depressions, and deep T-wave inversions, which often mimic the presentation of hypertrophic cardiomyopathy or myocardial ischemia. Furthermore, this review discusses the evolution of conduction disturbances, including atrioventricular blocks and atrial fibrillation, while emphasizing the absolute necessity of Holter monitoring for effective arrhythmia risk stratification. The impact of enzyme replacement therapy (ERT) on the stabilization of ECG patterns is evaluated, indicating that early clinical intervention is crucial for the prevention of irreversible electrical remodeling. In conclusion, despite the ongoing development of advanced imaging modalities, the standard 12-lead ECG remains a fundamental and indispensable tool that shortens the diagnostic odyssey and allows for the precise monitoring of treatment efficacy in Fabry disease.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessTHE ROLE OF ELECTROCARDIOGRAPHY IN THE DIAGNOSIS AND MONITORING OF FABRY DISEASE: A COMPREHENSIVE REVIEW
Anderson-Fabry disease (FD) is a rare, X-linked lysosomal storage disorder in which the progressive accumulation of globotriaosylceramide (Gb3) leads to widespread multi-organ damage, with cardiac involvement serving as the primary cause of mortality. This comprehensive review aims to summarize the current state of knowledge regarding the clinical application of electrocardiography (ECG) as a pivotal and cost-effective tool in the management of patients with FD. The paper systematically categorizes ECG findings across the various stages of the disease's progression. Early stages are typically characterized by a shortened PR interval and increased QRS complex voltages, which frequently manifest prior to the development of structural changes identifiable through echocardiography. In the more advanced stages of the disease, the predominant features include signs of left ventricular hypertrophy (LVH), ST-segment depressions, and deep T-wave inversions, which often mimic the presentation of hypertrophic cardiomyopathy or myocardial ischemia. Furthermore, this review discusses the evolution of conduction disturbances, including atrioventricular blocks and atrial fibrillation, while emphasizing the absolute necessity of Holter monitoring for effective arrhythmia risk stratification. The impact of enzyme replacement therapy (ERT) on the stabilization of ECG patterns is evaluated, indicating that early clinical intervention is crucial for the prevention of irreversible electrical remodeling. In conclusion, despite the ongoing development of advanced imaging modalities, the standard 12-lead ECG remains a fundamental and indispensable tool that shortens the diagnostic odyssey and allows for the precise monitoring of treatment efficacy in Fabry disease.